Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. clinical trials
A subsidiary of Sino Biopharmaceutical Limited
The registry lists 18 studies whose lead sponsor is Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.. 15 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 16, 2026.
Where
- China
- 18
Registry sponsor names on this page
- Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.18 studies
Something wrong with this grouping? Tell us on the Sino Biopharmaceutical Limited page.
Studies
Recruiting first, then most recently updated. Showing 18 of 18. All Sino Biopharmaceutical Limited studies →
- A Phase 2a Study of Kylo-0603 Capsule in Participants With Metabolic Dysfunction Associated Steatotic Liver Disease (MASLD)Not yet recruitingNCT07878091Phase 2
Sponsor listed in the registry: Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
- TQB2922 Injection Given Under the Skin With Chemotherapy as Initial Treatment for Colorectal Cancer That Has SpreadNot yet recruitingNCT07844187Phase 1/2
Sponsor listed in the registry: Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
- A Clinical Trial of TQB6426 for Injection in Patients With Advanced Solid TumorsRecruitingNCT07730190Phase 1
Sponsor listed in the registry: Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
- Clinical Trial of TQB2922 Injection (Subcutaneous Injection) in Patients With Advanced CancersRecruitingNCT07260708Phase 1
Sponsor listed in the registry: Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
- A Clinical Trial of TQF6422 Injection in Overweight or Obese Healthy Subjects.Not yet recruitingNCT07794111Phase 1
Sponsor listed in the registry: Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
- TQC2731 Clinical Trial for the Treatment of Severe Asthma With InjectionRecruitingNCT06829784Phase 3
Sponsor listed in the registry: Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
- Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.RecruitingNCT07385703Phase 3
Sponsor listed in the registry: Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
- Clinical Trial Comparing TQB2868 Injection Combined With Anlotinib Hydrochloride Capsules With Placebo Combined With Chemotherapy as First-line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)RecruitingNCT07165951Phase 3
Sponsor listed in the registry: Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
- Treatment of Recurrent/Metastatic Head and Neck CancerNot yet recruitingNCT07601204Phase 1/2
Sponsor listed in the registry: Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
- Assessment of the Efficacy and Safety of Injectable TQB2934 (Subcutaneous Injection) in Systemic Light Chain Amyloidosis PatientsRecruitingNCT07266116Phase 1/2
Sponsor listed in the registry: Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
- Clinical Study on TQH2722 Injection Combined With Background Therapy for Seasonal Allergic RhinitisRecruitingNCT07398859Phase 2
Sponsor listed in the registry: Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
- Clinical Trial of TQC2731 Injection in Patients With Chronic Sinusitis and Nasal PolypsRecruitingNCT07107256Phase 3
Sponsor listed in the registry: Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
- Evaluation of the Efficacy and Safety of TQB2825 Injection Compared to Immunotherapy in the Treatment of Recurrent/Refractory Follicular LymphomaNot yet recruitingNCT07187960Phase 3
Sponsor listed in the registry: Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
- Phase I Clinical Trial of TQB2825 Subcutaneous Injection in CD20-positive Hematological MalignanciesNot yet recruitingNCT07110194Phase 1
Sponsor listed in the registry: Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
- Clinical Trial of TQB2825 Injection Combined With Chemotherapy in Subjects With Diffuse Large B-cell LymphomaRecruitingNCT06854445Phase 2
Sponsor listed in the registry: Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
- To Evaluate the Phase III Clinical Trial of TQH2722 Injection in the Treatment of Moderate to Severe Atopic DermatitisActive, not recruitingNCT06552520Phase 3
Sponsor listed in the registry: Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
- A Clinical Study of TQC2731 Injection in Patients With Moderate to Severe Chronic Obstructive Pulmonary DiseaseActive, not recruitingNCT06707883Phase 2
Sponsor listed in the registry: Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
- Clinical Trial of TQH2722 Injection in Patients With Seasonal Allergic RhinitisCompletedNCT06760182Phase 2
Sponsor listed in the registry: Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.